Advertisement

Hypersensitivity to Fludrocortisone Acetate in a Recipient of Bone Marrow Transplantation.

00:42 EDT 18th June 2013 | BioPortfolio

Summary of "Hypersensitivity to Fludrocortisone Acetate in a Recipient of Bone Marrow Transplantation."

No Summary Available

Affiliation

Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

Journal Details

This article was published in the following journal.

Name: Allergology international : official journal of the Japanese Society of Allergology
ISSN: 1440-1592
Pages:

Links

Medical and Biotech [MESH] Definitions

Transplantation Conditioning

Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.

Myeloablative Agonists

Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.

Bone Marrow Transplantation

The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.

Hematopoietic Stem Cell Transplantation

Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.

Bone Marrow Purging

Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.

PubMed Articles [ 16111 Associated PubMed Articles listed on BioPortfolio]

Donor bone marrow-derived stem cells contribute to oral squamous cell carcinoma transformation in a recipient after hematopoietic stem cell transplantation.

Invariant NKT Cells Are Required for Antitumor Responses Induced by Host-Versus-Graft Responses.

Based on clinical observations, we have previously shown in a murine model that recipient leukocyte infusion (RLI) induces a host-versus-graft reaction in mixed bone marrow chimeras and that rejection...

Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children.

We describe long-term disease-free survival after unrelated donor bone marrow transplantation (BMT) for myelodysplastic syndrome (MDS) in 118 patients aged

The requirement for NKG2D in NK cell-mediated rejection of parental bone marrow grafts is determined by inhibitory receptors for MHC class I expressed by the graft recipient.

NK cells provide a unique barrier to semi-allogeneic bone marrow transplantation. In the setting where the parents donate to the F1 offspring, rejection of parental bone marrow occurs. This 'hybrid re...

Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL.

Clinical Trials [ 3562 Associated Clinical Trials listed on BioPortfolio]

Thymic Tolerance in Pediatric Heart Transplantation

The investigators hypothesize that injecting donor bone marrow cells into the recipient thymus gland at the time of heart transplantation in children will prove to be feasible and safe. Th...

Bone Marrow Transplantation in Treating Patients With Leukemia

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Randomized phase II...

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to s...

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

RATIONALE: Bone marrow that has been treated to remove certain white blood cells may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPO...

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

RATIONALE: Bone marrow from donors may be able to treat patients with severe aplastic anemia and patients whose bodies have rejected previous bone marrow transplantation. PURPOSE: Phase I...

Search BioPortfolio:
Advertisement
Advertisement